Agilent (A) Earnings And Revenues Surpass Estimates In Q4
Zacks Investment Research | Nov 26, 2019 05:46AM ET
Agilent Technologies’ (NYSE:A) fiscal fourth-quarter 2019 earnings of 89 cents per share surpassed the Zacks Consensus Estimate by 3 cents. In addition, the bottom line increased 17.1% sequentially and 9.9% year over year.
Fiscal fourth-quarter 2019 revenues of $1.37 billion increased 6% year over year (up 4% on a core basis). Also, the reported revenues — which came in above management’s guided range of $1.31-$1.33 — surpassed the Zacks Consensus Estimate of $1.33 billion.
The year-over-year revenue growth was driven by strength in pharma, diagnostics, environmental and forensics markets.
During the quarter, Agilent closed the acquisition of BioTek Instruments, Inc., a provider of life science instrumentation. This deal will expand the company’s presence in the life science research space. It will also strengthen Agilent’s offerings related to live cell analysis as these product lines aid in quantification of biomolecules, biomolecular interactions and cellular structure.
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.